Intensive lipid lowering with high-dose 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) provides a significant benefit over standard-dose statin therapy in preventing nonfatal cardiovascular outcomes and also may reduce the incidence of cardiovascular death, according to results of a meta-analysis published in the Journal of the American College of Cardiology.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

High-dose statin therapy displays benefit in preventing cardiovascular events compared with standard doses

Newsletter